Oppenheimer Asset Management Inc. acquired a new stake in Masimo Co. (NASDAQ:MASI - Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 3,584 shares of the medical equipment provider's stock, valued at approximately $478,000.
Other large investors also recently modified their holdings of the company. Versor Investments LP raised its stake in Masimo by 81.7% in the third quarter. Versor Investments LP now owns 9,591 shares of the medical equipment provider's stock worth $1,279,000 after buying an additional 4,313 shares in the last quarter. State of New Jersey Common Pension Fund D grew its stake in Masimo by 1.2% in the third quarter. State of New Jersey Common Pension Fund D now owns 16,736 shares of the medical equipment provider's stock worth $2,231,000 after purchasing an additional 194 shares during the period. Crossmark Global Holdings Inc. raised its holdings in Masimo by 14.4% in the third quarter. Crossmark Global Holdings Inc. now owns 3,248 shares of the medical equipment provider's stock worth $433,000 after purchasing an additional 409 shares in the last quarter. Montanaro Asset Management Ltd lifted its position in Masimo by 3.7% during the third quarter. Montanaro Asset Management Ltd now owns 55,700 shares of the medical equipment provider's stock valued at $7,426,000 after buying an additional 2,000 shares during the period. Finally, Assetmark Inc. boosted its holdings in shares of Masimo by 12.7% during the 3rd quarter. Assetmark Inc. now owns 1,183 shares of the medical equipment provider's stock valued at $158,000 after buying an additional 133 shares in the last quarter. 85.96% of the stock is owned by institutional investors.
Masimo Stock Performance
NASDAQ:MASI traded up $1.45 during mid-day trading on Wednesday, reaching $164.95. The company's stock had a trading volume of 526,617 shares, compared to its average volume of 676,894. The company has a current ratio of 2.01, a quick ratio of 1.11 and a debt-to-equity ratio of 0.50. The stock has a market cap of $8.83 billion, a P/E ratio of 113.76 and a beta of 0.97. The firm's fifty day moving average price is $140.14 and its two-hundred day moving average price is $127.20. Masimo Co. has a 12-month low of $91.60 and a 12-month high of $173.90.
Masimo (NASDAQ:MASI - Get Free Report) last released its quarterly earnings data on Tuesday, November 5th. The medical equipment provider reported $0.98 earnings per share for the quarter, beating the consensus estimate of $0.84 by $0.14. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The firm had revenue of $504.60 million during the quarter, compared to analysts' expectations of $502.87 million. During the same period in the previous year, the company earned $0.63 earnings per share. The firm's quarterly revenue was up 5.4% on a year-over-year basis. On average, equities analysts forecast that Masimo Co. will post 4.04 EPS for the current fiscal year.
Wall Street Analyst Weigh In
MASI has been the subject of a number of analyst reports. BTIG Research raised their target price on shares of Masimo from $166.00 to $170.00 and gave the company a "buy" rating in a research note on Monday, October 14th. Wells Fargo & Company raised their price objective on Masimo from $160.00 to $171.00 and gave the company an "overweight" rating in a research report on Wednesday, November 6th. Raymond James raised Masimo from a "market perform" rating to an "outperform" rating and set a $170.00 target price on the stock in a research note on Wednesday, November 6th. Piper Sandler upped their price target on shares of Masimo from $165.00 to $180.00 and gave the stock an "overweight" rating in a research note on Wednesday, November 6th. Finally, Needham & Company LLC restated a "hold" rating on shares of Masimo in a research note on Wednesday, November 6th. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $163.67.
Check Out Our Latest Stock Analysis on Masimo
About Masimo
(
Free Report)
Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.
Featured Stories
Before you consider Masimo, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Masimo wasn't on the list.
While Masimo currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
